VaxInnate Corporation

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, VaxInnate Corporation sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

VaxInnate Corporation: 9 sponsored US clinical trials, none currently recruiting.

VaxInnate Corporation sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Influenza, with 1 trials.

Top-decile sponsor footprint

VaxInnate Corporation ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

COMPLETED Phase 1

Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49

NCT01658800
COMPLETED Phase 1

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

NCT01560793
COMPLETED Phase 1

Comparative Safety and Immunogenicity of VAX128A, VAC128B and VAX128C Novel H1N1 Influenza Vaccine in Healthy Adults

NCT01172054
COMPLETED Phase 2

Safety and Immunogenicity of VAX125 Influenza Vaccine in Community-living Adults >= 65 Years of Age

NCT00966238
COMPLETED Phase 1

Study to Investigate the Immune Response to Two Doses of VAX102 Healthy Adults

NCT00921206
COMPLETED Phase 1

Safety of VAX102 Vaccine Given With Seasonal Flu Vaccine in Healthy Adults

NCT00921973
COMPLETED Phase 1

Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults

NCT00921947
COMPLETED Phase 1

Phase 1 Safety and Immunogenicity Study in Healthy Adults of VAX125, a Recombinant HA-flagellin Influenza Vaccine

NCT00730457
COMPLETED Phase 1

Phase I Safety and Immunogenicity Study of VAX102 [Flagellin.HuM2e] Influenza Vaccine in Healthy Adults

NCT00603811

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 1

Therapeutic Areas

Influenza 1

How the VaxInnate Corporation early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 9 completed (100%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Influenza (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

VaxInnate Corporation: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

VaxInnate Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share VaxInnate Corporation4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
VaxInnate Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

VaxInnate Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this VaxInnate Corporation page

9 registered trials is a research-attention snapshot, not an endorsement of VaxInnate Corporation or any single study.

  • None of VaxInnate Corporation's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Influenza is the condition VaxInnate Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Influenza trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

VaxInnate Corporation pipeline card: 9 registered trials from official public datasets.Report a data error.